Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Thoracic 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 243Leukemia, Myeloid, Acute 191Leukemia 145Leukemia, Myelogenous, Chronic, BCR-ABL Positive 139Precursor Cell Lymphoblastic Leukemia-Lymphoma 120Myeloproliferative Disorders 89Multiple Myeloma 84Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Primary Myelofibrosis 72Leukemia, Myelomonocytic, Chronic 68Lymphoma 67Hodgkin Disease 66Leukemia, Myeloid, Chronic-Phase 55Lymphoma, Mantle-Cell 50Blast Crisis 49Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Follicular 44Leukemia, Myeloid, Accelerated Phase 44Congenital Abnormalities 41Lymphoma, B-Cell, Marginal Zone 40Burkitt Lymphoma 40Neoplasms, Plasma Cell 38Lymphoma, Large-Cell, Immunoblastic 35Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 35Polycythemia Vera 32Hematologic Neoplasms 31Myelodysplastic-Myeloproliferative Diseases 30Lymphoma, T-Cell, Cutaneous 29Anemia, Refractory, with Excess of Blasts 29

Interventions

Therapeutics 1PLX8394 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Histiocytosis × Myeloid × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

NCT01050439 2015-04-15

Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Columbia University

Phase 2 Terminated
22 enrolled
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡